CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.22852911

Available online at: http://www.iajps.com Review Article

IMPACT OF SCHEDULE M AMENDMENTS ON PHARMACEUTICAL MANUFACTURING PROCESSES IN INDIA.

Akulapelly Thrisha[1*] & G.Kamal Yadav[2]

[1]Department Of Regulatory Affairs , Vaagdevi Pharmacy College,Bollikunta, Warangal, Telangana, India, 506005.

[2]Principal, Vaagdevi Pharmacy College,Bollikunta, Warangal, Telangana, India, 506005

Abstract:

*The recent amendments to **Schedule M** of the Drugs and Cosmetics Rules, 1945 represent a significant regulatory milestone aimed at strengthening India's pharmaceutical manufacturing framework in alignment with global quality standards such as **WHO-GMP** and **PIC/S** guidelines. These revisions emphasize enhanced **Good Manufacturing Practices (GMP)**, risk-based approaches, and data integrity requirements to ensure product quality, patient safety, and international regulatory compliance.*

*This study examines the **impact of Schedule M amendments** on pharmaceutical manufacturing processes in India, focusing on changes in facility design, documentation practices, quality management systems, validation protocols, and technology adoption. The research further explores the implications for small and medium enterprises (SMEs), cost considerations, compliance timelines, and the transition challenges faced by industry stakeholders. By comparing the pre- and post-amendment frameworks, the analysis highlights the potential improvements in manufacturing robustness, reduction in product recalls, and increased global competitiveness of Indian pharmaceutical exports.*

The findings suggest that while the revised Schedule M enhances regulatory oversight and manufacturing excellence, effective implementation will depend on capacity building, regulatory harmonization, and industry readiness. The amendments are expected to transform the Indian pharmaceutical sector into a more quality-driven and globally trusted industry.

Keywords: *Schedule M amendments, Good Manufacturing Practices (GMP), pharmaceutical manufacturing, regulatory compliance, quality management system (QMS), WHO-GMP alignment, data integrity, India, pharmaceutical industry, PIC/S standards*

Corresponding author:
Akulapelly Thrisha,
Department of Regulatory Affairs, Vaagdevi Pharmacy College, Warangal, Telangana
Mobile:
Email Id-

QR CODE

*Please cite this article in press **Akulapelly Thrisha** et al., Impact Of Schedule M Amendments On Pharmaceutical Manufacturing Processes In India.,. Indo Am. J. P. Sci, 2026; 13(09).*

INTRODUCTION:

1. Introduction to Pharmaceutical Manufacturing in India

1.1 Historical Evolution of Pharmaceutical Manufacturing

The pharmaceutical industry in India has evolved from a fragmented collection of small formulators in the post-Independence era into one of the most dynamic global manufacturing ecosystems. In the 1950s and 1960s, the Indian market was dominated by multinational corporations (MNCs) that held product patents and dictated high drug prices. The enactment of the **Indian Patents Act (1970)** was a watershed moment: it recognized only process patents, allowing domestic firms to develop alternate manufacturing routes for existing drugs. This legislation encouraged indigenous innovation, price competition, and the rise of domestic leaders such as Cipla, Ranbaxy, and Dr. Reddy's Laboratories (Chaudhuri, 2005; Kumar & Singh, 2018).

During the 1980s, India invested in bulk-drug synthesis capabilities and active pharmaceutical ingredient (API) production. Public sector undertakings like Hindustan Antibiotics Ltd. and Indian Drugs and Pharmaceuticals Ltd. strengthened self-reliance. The liberalization of the Indian economy in the early 1990s further accelerated industrial growth and technology transfer, coinciding with the establishment of the **Central Drugs Standard Control Organisation (CDSCO)** as the national regulatory authority. The CDSCO's role in licensing, quality monitoring, and clinical oversight became critical to harmonizing domestic manufacturing with global norms (CDSCO, 2024).

With India's accession to the **World Trade Organization (WTO)** and compliance with the **Trade-Related Aspects of Intellectual Property Rights (TRIPS)** agreement in 2005, product patents were re-introduced. Indian companies responded by investing heavily in research and development (R&D), new drug delivery systems, and regulatory-compliant facilities certified under Schedule M of the *Drugs and Cosmetics Rules (1945)*. This regulatory evolution marked the beginning of India's transition from a generics-driven model to an innovation-supportive manufacturing hub (Gupta et al., 2019).

1.2 India's Current Position in the Global Pharmaceutical Landscape

India today occupies a pre-eminent position as the **world's third-largest producer of pharmaceuticals by volume** and **thirteenth by value** (Pharmexcil, 2024). The country supplies approximately **60 percent of global vaccine demand** and **20 percent of worldwide generic medicines**. Exports exceeded **USD 27 billion in 2023–24**, with major markets including North America, the European Union, Africa, and Latin America (PIB, 2024).

The nation hosts more than **10,500 manufacturing units**, of which over **600 facilities are approved by stringent regulatory authorities** such as the U.S. Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). These approvals affirm India's adherence to internationally recognized quality systems and underscore its role as the "pharmacy of the world."

Government initiatives such as **Make in India**, **Atmanirbhar Bharat**, and the **Production Linked Incentive (PLI)** scheme have strengthened domestic manufacturing infrastructure and encouraged backward integration for critical APIs. The **Jan Aushadhi** program has expanded access to affordable generic medicines for millions, demonstrating how regulatory and industrial growth can directly impact public health outcomes (MoHFW, 2024).

1.3 Technological Transformation and Modern Manufacturing Practices

In the last decade, Indian pharmaceutical manufacturing has experienced a technological renaissance. The integration of **Quality by Design (QbD)**, **Process Analytical Technology (PAT)**, and **Continuous Manufacturing** principles has shifted the emphasis from end-product testing to real-time process control and quality assurance (Patel et al., 2022). Automation, robotics, and artificial intelligence are being gradually incorporated to monitor environmental parameters, equipment performance, and data integrity.

Digitalization initiatives—such as electronic batch records, enterprise resource planning (ERP) systems, and computerized maintenance management—have enhanced traceability and reduced human error. The emergence of **Industry 4.0** in pharma (often termed *Pharma 4.0*) has connected production, quality, and regulatory compliance through smart sensors and analytics (Singh & Kaur, 2023). These advances, however, have also necessitated more rigorous regulatory oversight, particularly in areas of data governance and cybersecurity.

The 2024 Schedule M amendments explicitly recognize these shifts, incorporating concepts of **data integrity**, **risk-based validation**, and **holistic quality management systems (QMS)** that align Indian GMP with **World Health Organization (WHO)** and **Pharmaceutical Inspection Co-operation Scheme (PIC/S)** guidelines.

1.4 Regulatory Oversight and Institutional Framework

India's pharmaceutical regulatory architecture is multilayered. The **Ministry of Health and Family Welfare (MoHFW)** oversees the implementation of the *Drugs and Cosmetics Act (1940)* and its subordinate *Rules (1945)*. The **CDSCO**, headed by the **Drugs Controller General of India (DCGI)**, is responsible for central licensing, GMP inspections, and import/export regulation. State FDAs supervise local manufacturing units and retail distribution.

The **National Accreditation Board for Testing and Calibration Laboratories (NABL)** accredits quality-control laboratories, ensuring compliance with ISO/IEC 17025 standards. Parallel agencies—such as the **Indian Pharmacopoeia Commission (IPC)** and the **Pharmaceuticals Export Promotion Council (Pharmexcil)**—support quality benchmarking and export promotion, respectively (CDSCO, 2024; Pharmexcil, 2024).

Despite these institutional structures, periodic global inspection findings have revealed inconsistencies in documentation, sanitation, and data management practices, particularly among small and medium enterprises (SMEs). These issues prompted the Government of India to modernize Schedule M to create a uniform, risk-based compliance system adaptable to the scale of operations.

1.5 Quality Culture and the Role of GMP in Manufacturing Excellence

Good Manufacturing Practices (GMP) form the cornerstone of pharmaceutical quality assurance. Schedule M stipulates detailed requirements for premises, equipment, sanitation, documentation, validation, and personnel hygiene. The intent is to ensure that drugs are consistently produced and controlled according to predetermined quality standards appropriate for their intended use (CDSCO, 2024).

GMP compliance is not merely a regulatory requirement but a business imperative that determines market credibility. Regulatory agencies in the United States, Europe, and Japan demand evidence of robust GMP systems before approving imports. Several Indian firms have faced warning letters, import alerts, or recalls due to data-integrity lapses or inadequate environmental control (Jain & Mehta, 2022). Such incidents have reinforced the necessity of instilling a culture of quality—one that values documentation accuracy, employee training, and proactive risk management.

The revised Schedule M framework thus emphasizes a **Quality Management System (QMS)** encompassing **Quality Risk Management (QRM)**, **Corrective and Preventive Actions (CAPA)**, and **Management Review**—concepts drawn from ICH Q9 (R1) and ISO 9001 standards. By embedding these principles, the amendment seeks to move the industry from compliance-driven behavior to continuous quality improvement.

1.6 Economic and Social Significance of the Pharmaceutical Sector

Pharmaceutical manufacturing is a strategic pillar of India's economy, contributing approximately **1.7 percent to national GDP** and employing over **2.5 million people** directly and indirectly (PIB, 2024). The sector underpins national healthcare delivery through affordable drug supply, including essential medicines for communicable and non-communicable diseases.

During the COVID-19 pandemic, India's ability to scale vaccine production rapidly—particularly through the Serum Institute of India and Bharat Biotech—demonstrated the robustness of its manufacturing base and global responsibility. However, the pandemic also exposed systemic vulnerabilities, including dependence on imported intermediates, variable quality infrastructure, and limited regulatory digitalization. These learnings have significantly influenced the latest Schedule M reforms, which prioritize supply-chain transparency, environmental control, and process validation for pandemic resilience.

1.7 Need for a Modernized Regulatory Framework

While Schedule M has long provided the regulatory foundation for GMP compliance, the earlier version (last comprehensively revised in 2001) lagged behind international benchmarks. Over the last two decades, global GMP standards have evolved to emphasize **quality systems**, **risk management**, and **data integrity**, whereas Indian regulations remained largely static. Consequently, there arose an urgent need to upgrade Schedule M to ensure equivalence with WHO GMP (2023) and PIC/S GMP (PE 009-15) guidelines (WHO, 2023).

The **2024 amendment** introduced by the MoHFW reflects a paradigm shift—from prescriptive facility-based controls to performance-based quality outcomes. The revised norms mandate a written quality policy, internal audits, product-quality reviews, and enhanced documentation practices. Importantly, they introduce scalability: small manufacturers are given a phased transition period to achieve compliance without disrupting supply continuity.

I. 2. Overview of Schedule M

2.1 Origin and Legislative Background

The concept of Schedule M derives its legal authority from the **Drugs and Cosmetics Act, 1940**, and the corresponding **Drugs and Cosmetics Rules, 1945**—the principal regulatory instruments governing the manufacture, sale, and distribution of pharmaceuticals in India. When these rules were originally framed, India's pharmaceutical manufacturing capacity was limited, and there was minimal emphasis on standardization or quality management. To ensure that drugs manufactured and sold in the country met acceptable standards of safety and efficacy, the Government of India progressively introduced various schedules to the rules, each specifying requirements for different product categories or activities.

Schedule M, first notified in the **1960s**, was formulated to establish **Good Manufacturing Practices (GMP)** for pharmaceuticals. The primary objective was to ensure that all drugs produced in India were manufactured under sanitary conditions and possessed the strength, quality, and purity claimed on their labels. The introduction of Schedule M marked a pivotal shift from mere product-based regulation to **process-based regulation**, emphasizing the environment, equipment, personnel, and documentation involved in drug production (CDSCO, 2024).

The legal basis for enforcement lies in **Rule 71 and Rule 76** of the *Drugs and Cosmetics Rules (1945)*, which require manufacturers to comply with the standards prescribed under Schedule M as a condition for obtaining or renewing a manufacturing license. Noncompliance can result in suspension or cancellation of licenses under **Section 18** of the Act. Thus, Schedule M serves as a statutory mandate rather than a voluntary code of practice (MoHFW, 2024).

2.2 Evolution of Schedule M Revisions

Since its inception, Schedule M has undergone several amendments to align with advances in pharmaceutical science and international GMP principles.

The **first comprehensive revision** occurred in **1988**, focusing on basic facility design, sanitation, equipment qualification, and record maintenance. However, the limited awareness of GMP concepts among small manufacturers and the absence of a risk-based regulatory framework hindered uniform compliance.

The **2001 revision**, implemented in **2003**, was the most transformative prior to the recent 2024 update. This version expanded the scope of GMP requirements, introducing mandatory validation, documentation control, and product recall systems. It aligned partially with **World Health Organization (WHO)** GMP guidelines and **United States FDA** principles but lacked harmonization with **European Union (EU)** and **Pharmaceutical Inspection Co-operation Scheme (PIC/S)** standards (Kumar et al., 2017).

The **2024 amendment**, published by the **Ministry of Health and Family Welfare (MoHFW)**, represents the first major overhaul in over two decades. It reflects global expectations on **quality management systems (QMS)**, **risk assessment**, **data integrity**, and **environmental controls**. Unlike earlier revisions, it explicitly categorizes GMP requirements for different manufacturing scales and product types, providing **flexibility for micro, small, and medium enterprises (MSMEs)** while ensuring progressive compliance (MoHFW, 2024).

This modernization aims to align Schedule M with **WHO-GMP (2023)** and **PIC/S PE 009-15 (2021)** frameworks, thereby facilitating global recognition of Indian manufacturing facilities and improving export competitiveness.

2.3 Structure and Components of Schedule M

Schedule M is divided into multiple **parts and appendices**, each addressing specific aspects of pharmaceutical manufacturing. The general structure comprises:

- **Part I:** *Good Manufacturing Practices for Premises and Materials* – outlining design, maintenance, and environmental controls for manufacturing areas.
- **Part IA:** *Specific Requirements for Manufacture of Various Dosage Forms* – including tablets, capsules, parenterals, ointments, and liquid or sterile preparations.
- **Part IB:** *Requirements for Manufacture of Active Pharmaceutical Ingredients (APIs) and Bulk Drugs.*
- **Part II:** *Requirements for Cosmetics.*

- **Appendices:** Covering documentation formats, validation protocols, sanitation procedures, and self-inspection checklists.

The Schedule defines core GMP components such as:

1. **Personnel:** Qualification, training, and hygiene requirements for staff.
2. **Premises:** Layouts that prevent cross-contamination, with dedicated areas for different operations.
3. **Equipment:** Design, cleaning, and maintenance protocols to prevent mix-ups.
4. **Sanitation and Hygiene:** Routine cleaning, pest control, and environmental monitoring.
5. **Documentation:** Procedures for recording batch manufacturing and testing data.
6. **Quality Control (QC):** Independent evaluation of raw materials, intermediates, and finished products.
7. **Complaints and Recalls:** Systems for investigating product quality issues and initiating corrective actions.
8. **Self-Inspection:** Internal audits to ensure continuous compliance.

The **2024 version** introduces three additional pillars:

- **Quality Management System (QMS):** Emphasizing management commitment, change control, and continuous improvement.
- **Quality Risk Management (QRM):** Based on ICH Q9 (R1), focusing on proactive identification and mitigation of quality risks.
- **Data Integrity:** Requiring validation of electronic systems and audit trails to prevent data manipulation or loss.

These additions signify India's transition from a procedural compliance regime to a performance- and risk-based GMP culture.

2.4 Scope and Applicability

Schedule M applies to all manufacturers of:

- **Pharmaceutical formulations** (solid, liquid, and parenteral dosage forms)
- **Bulk drugs and active pharmaceutical ingredients (APIs)**
- **Herbal and traditional medicines** (Ayurvedic, Siddha, Unani) in adapted forms
- **Cosmetics** (as specified under Part II)

However, the degree of implementation may vary depending on the nature and scale of operations. For example, while large multinational plants typically follow global GMP norms, smaller units often struggle with infrastructural investments and technical expertise. Recognizing this, the 2024 amendment introduces **graded timelines** and **capacity-building programs** for MSMEs through state regulators and CDSCO training initiatives (CDSCO, 2024).

The applicability of Schedule M also extends to **contract manufacturing**, **loan licensing**, and **third-party manufacturing**—sectors that have grown substantially in India's generics landscape. Contract manufacturers are now explicitly required to demonstrate GMP compliance equivalent to that of the marketing authorization holder, ensuring uniform quality across supply chains.

2.5 Alignment with Global GMP Frameworks

Globally, GMP standards are harmonized under various frameworks, including:

- **WHO-GMP (2023 Revision)**
- **European Union (EU-GMP) EudraLex Volume 4**
- **U.S. FDA Current Good Manufacturing Practices (cGMP)**
- **PIC/S GMP Guide (PE 009-15)**

The 2024 Schedule M update represents a deliberate effort to align India's domestic standards with these international benchmarks. Key areas of convergence include:

- Adoption of **QMS and QRM** principles from ICH Q10 and Q9 (R1).
- Inclusion of **validation lifecycle management** similar to EU Annex 15.
- Strengthened **data integrity** requirements consistent with FDA 21 CFR Part 11.
- Mandatory **product quality review (PQR)** and **management review** systems found in PIC/S GMP.

This harmonization has two major implications:

1. **Facilitating global regulatory acceptance**, as Indian manufacturers can demonstrate equivalence with WHO and PIC/S standards during foreign inspections.
2. **Enhancing domestic quality assurance**, leading to improved patient safety and reduced risk of product recalls or international sanctions.

2.6 Importance of Schedule M as a Foundational Regulatory Instrument

Schedule M is more than a procedural guideline—it is the operational backbone of India's pharmaceutical manufacturing ecosystem. Compliance ensures that every step in the production chain, from raw material sourcing to batch release, is governed by documented and validated practices. Moreover, it provides a **legal framework for accountability**, linking manufacturers, quality-control personnel, and regulators under a shared responsibility for public health.

The modernized Schedule M strengthens this accountability by introducing **management-level responsibility**, **continuous training**, and **self-auditing mechanisms**. These features collectively foster a "culture of quality," a prerequisite for sustaining India's global pharmaceutical leadership.

I. 3. Rationale for Schedule M Amendments

3.1 Identified Gaps in the Earlier Framework

Before the 2024 revision, the previous version of Schedule M—last substantially updated in 2001—was increasingly seen as outdated and inadequate in addressing modern pharmaceutical manufacturing challenges. The regulatory landscape, both globally and domestically, had evolved dramatically over two decades, with rapid advances in process automation, data integrity systems, and risk-based quality management. In contrast, the earlier Schedule M relied heavily on **prescriptive facility design requirements** rather than a **system-based approach to quality**.

Several limitations were evident in the earlier framework:

- **Lack of emphasis on Quality Management Systems (QMS)**: While it detailed premises, equipment, and documentation, it did not establish a structured QMS encompassing risk management, deviation handling, and continual improvement (CDSCO, 2023).
- **Inadequate provisions for data integrity and computerized systems**: The earlier version lacked guidelines on electronic records, audit trails, or validation of computerized systems, which have become essential in the digital manufacturing era (Jain & Mehta, 2022).
- **Insufficient risk management principles**: Global GMP frameworks, such as ICH Q9 (R1), emphasize proactive risk assessment, but this concept was absent in earlier Schedule M versions.
- **Limited adaptability to new dosage forms**: The previous rules did not adequately address complex biologics, novel drug delivery systems (NDDS), or continuous manufacturing technologies.
- **No scalability for MSMEs**: Small and medium enterprises (SMEs), which constitute nearly 70% of India's manufacturing base, faced challenges complying with rigid infrastructure norms not tailored to their operational scale (Pharmexcil, 2024).

Consequently, while Schedule M compliance provided a basic assurance of product quality, it lagged behind contemporary international practices and did not sufficiently prevent quality incidents that could affect both domestic and export credibility.

DISCUSSION

The revision of **Schedule M under the Drugs and Cosmetics Rules, 1945**, finalized in **December 2023 and implemented in 2024**, represents one of the most significant regulatory transformations in India's pharmaceutical history. The amendment seeks to bring domestic **Good Manufacturing Practices (GMPs)** into alignment with **World Health Organization (WHO)** and **Pharmaceutical Inspection Co-operation Scheme (PIC/S)** standards.

This discussion critically analyzes how these amendments influence **pharmaceutical manufacturing processes**, **quality assurance systems**, and **industry competitiveness** in India. The findings integrate theoretical frameworks from **quality management, regulatory science, and industrial modernization**, emphasizing how these reforms can reshape India's position as a global supplier of affordable and high-quality medicines.

Overview of Schedule M Amendments (2024)

Prior to the amendment, Schedule M (last revised in 2001) outlined basic GMP requirements focusing largely on physical infrastructure and hygiene. However, international GMP systems had evolved considerably over two decades—introducing structured approaches like **Pharmaceutical Quality System (PQS)**, **Quality**

Risk Management (QRM), and **Data Integrity** (WHO, 2023; CDSCO, 2024).

The 2024 revision bridges this gap by:

1. Integrating **ICH Q8–Q10** principles into Indian GMP standards.
2. Mandating **continuous process verification**, **digital record keeping**, and **risk-based inspections**.
3. Requiring manufacturers to establish **quality culture frameworks**, ensuring accountability at every level.

These changes represent a paradigm shift from **compliance-based manufacturing** to **science- and risk-based quality management** (IPA, 2023).

Rationale and Global Context of GMP Modernization

India's pharmaceutical exports exceed **USD 25 billion annually**, reaching over 200 countries (Pharmexcil, 2024). However, over the past decade, multiple Indian facilities faced **import alerts** and **Form 483 observations** from the USFDA and EU regulators, often citing GMP deficiencies.

Such incidents underscored systemic issues: outdated infrastructure, insufficient data control, and limited regulatory harmonization. The **revised Schedule M** thus serves as both a corrective and proactive step—modernizing India's manufacturing practices to meet **global trust and market access standards** (WHO, 2024).

Furthermore, as India moves toward becoming a **pharma innovation hub**, particularly in biosimilars and complex generics, the regulatory foundation needed strengthening to sustain **product integrity and patient safety**.

Impact on Pharmaceutical Manufacturing Processes

The revised Schedule M has redefined how manufacturing operations are designed, validated, and managed across the product lifecycle.

Quality Management Systems and PQS Integration

A key feature of the amendment is the mandatory establishment of a **Pharmaceutical Quality System (PQS)** consistent with **ICH Q10**. This shifts the focus from procedural compliance to **systemic quality assurance** encompassing:

- Management responsibility and review.
- Change control, CAPA, and deviation trend analysis.
- Periodic product quality reviews.

Leading companies such as **Dr. Reddy's Laboratories** and **Cipla** have adopted **digital quality dashboards** to track deviations and trend CAPA outcomes, illustrating the transition toward a continuous improvement framework (Sharma & Gupta, 2024).

Quality Risk Management (QRM) and CAPA Strengthening

The integration of **QRM principles** ensures structured risk identification and mitigation at every manufacturing stage. Tools like **FMEA** (Failure Mode and Effects Analysis) and **HACCP** (Hazard Analysis and Critical Control Points) are becoming standard practice.

By quantifying risk levels associated with process parameters, firms can focus control strategies on **Critical Process Parameters (CPPs)** and **Critical Quality Attributes (CQAs)**. This approach aligns with **ICH Q9(R1)**, reducing batch failures and promoting reproducibility.

Facility and Equipment Modernization

The amendment redefines facility design expectations, including:

- Segregated production areas to prevent cross-contamination.
- Dedicated air-handling units (AHUs) for critical zones.
- Validation of HVAC, water systems, and cleanrooms.

These infrastructural updates, though capital-intensive, significantly enhance **product sterility assurance** and **contamination control**. Additionally, modern energy-efficient utilities align with India's **Green Pharma Mission 2030** (PIB, 2024).

Digitalization, Data Integrity, and AI Integration

Schedule M 2024 explicitly mandates **data integrity** under **ALCOA+ principles**—requiring all data to be *Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available*.

Manufacturers are transitioning toward **Manufacturing Execution Systems (MES)** and **Electronic Batch Records (EBR)** to ensure traceability and reduce manual errors. AI-based audit tools are being employed to detect anomalies, ensuring authenticity during regulatory inspections (Kumar & Patel, 2024).

These digital systems are expected to minimize documentation errors by over **30%**, enhancing both compliance and efficiency (MoHFW, 2024).

Workforce and Quality Culture Transformation

The success of GMP modernization depends not only on infrastructure but also on people. The amended Schedule M emphasizes **continuous training**, **competency assessment**, and **ethical accountability**.

Companies are required to implement structured GMP training programs with periodic evaluations. The development of **GMP academies** and **Quality Schools** by leading firms demonstrates a shift toward embedding quality culture.

Moreover, the regulatory emphasis on **Just Culture**—encouraging error reporting without fear—aligns with global trends in pharmaceutical ethics (Nair & Pillai, 2023).

Comparative Perspective: Schedule M vs. WHO-GMP & PIC/S

A comparative analysis shows that the 2024 Schedule M is substantially harmonized with WHO and PIC/S guidelines:

Regulatory Domain	Schedule M (2024)	WHO-GMP (2021)	PIC/S PE 009-15
Quality Management System	Mandatory PQS aligned with ICH Q10	Yes	Yes
Data Integrity	ALCOA+ compliance required	Yes	Yes
QRM Implementation	Required for all stages	Partial	Full
Validation	Lifecycle approach (CPV)	Yes	Yes
Training	Documented and evaluated	Yes	Yes
Environmental Sustainability	Integrated	Limited	Limited

This alignment ensures that Indian manufacturers can more easily pursue **WHO prequalification** and **PIC/S membership**, facilitating greater export opportunities (CDSCO, 2024).

Economic Implications: MSMEs vs. Large Manufacturers

Financial Burden on MSMEs

The modernization costs pose significant barriers for MSMEs, which constitute over **65% of India's pharma manufacturing base**. Compliance costs ranging from **INR 2–5 crore** may render smaller firms financially vulnerable.

While the government introduced **PTUAS** and **PLI 2.0 schemes**, limited awareness and bureaucratic procedures hinder accessibility (FICCI, 2024). Without targeted financial assistance, there is a risk of market consolidation favoring larger corporations.

Export Competitiveness

Conversely, harmonization with WHO-GMP increases global trust, allowing Indian companies to expand into regulated markets. Enhanced compliance may boost exports by **15–20%** over five years (Pharmexcil, 2024). Thus, short-term cost burdens may yield long-term economic resilience.

Regulatory Oversight and Inspection Dynamics

The implementation of a **risk-based inspection system** represents a regulatory modernization milestone. CDSCO now prioritizes facilities based on **product risk and compliance history**, employing centralized inspection databases and digital audit trails.

However, **inspector shortages**—with only 2,500 inspectors for 10,000+ plants—pose serious constraints (WHO, 2024). Strengthening inspection capacity through **AI-supported auditing**, **remote inspections**, and **cross-state coordination** will be critical for sustainable enforcement.

Implementation Challenges and Industry Readiness

Transitional challenges include:

- **Skill gaps** in QMS and data integrity systems.
- **Resistance to cultural change** from output-focused to quality-focused operations.
- **Inconsistent enforcement** among state regulators.

Inadequate training, delayed financing, and partial digitalization exacerbate these barriers. Overcoming them requires **joint public-private programs**, capacity-building workshops, and mentorship between large firms and SMEs (IDMA, 2023).

Environmental, Social, and Sustainability Aspects

The amended Schedule M includes clauses promoting **environmental management systems**, **waste reduction**, and **worker safety**. Compliance now requires monitoring air quality, waste disposal, and chemical exposure levels.

The integration of **green manufacturing principles** is consistent with global sustainability goals (SDG 9 & 12). Adoption of **zero-liquid-discharge technologies** and **energy-efficient HVAC systems** demonstrates convergence between regulatory compliance and corporate responsibility (PIB, 2024).

Policy and Strategic Recommendations

1. **Financial Inclusion for MSMEs:** Expand PTUAS grants and create low-interest "GMP Modernization Loans."
2. **Inspector Training Expansion:** Collaborate with WHO and PIC/S to train 1,000+ new GMP inspectors.
3. **GMP Digital India Initiative:** Develop national-level validated EBR/LIMS platforms for SMEs.
4. **Cluster-Based Modernization:** Create regional GMP hubs for shared validation and testing services.
5. **Academic Integration:** Introduce GMP and QRM modules in B.Pharm and M.Pharm curricula.

These strategies will ensure that regulatory reforms are inclusive, scalable, and sustainable.

Overall Interpretation and Theoretical Implications

The revised Schedule M exemplifies the **Regulatory Modernization Theory**, where evolving scientific knowledge and market dynamics necessitate periodic policy realignment. It also illustrates **Quality by Design (QbD)** principles, integrating risk management, lifecycle validation, and continuous monitoring as key components of manufacturing excellence.

Theoretically, this transition underscores the movement from **compliance-based regulation** to **performance-based governance**, aligning India's regulatory architecture with international best practices.

Summary of Key Findings

The 2024 Schedule M amendments significantly influence pharmaceutical manufacturing processes in India by:

- Embedding quality systems across the product lifecycle.
- Promoting technological modernization and digital compliance.
- Strengthening inspection mechanisms and transparency.
- Encouraging sustainability and workforce development.
- Enhancing export potential and global competitiveness.

While transitional challenges remain, the long-term outcome will be a **more resilient, accountable, and globally credible** pharmaceutical manufacturing ecosystem.

II. Challenges and Implementation Barriers

Despite its potential, the transition to the new regulatory regime presents several **challenges**.
Financial and Infrastructure Constraints

For small and medium pharmaceutical manufacturers, compliance costs represent a significant hurdle. The required infrastructural modifications—HVAC installation, automation,

environmental monitoring—demand **capital investments averaging ₹3–5 crores per unit** (FICCI, 2024). To offset this, the government launched the **Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS)**, offering financial aid and low-interest loans (Ministry of Chemicals and Fertilizers, 2024).

Workforce and Cultural Barriers

Many manufacturing facilities struggle with a shortage of trained personnel and resistance to change. Moving from manual systems to digital QMS requires both technical and cultural transformation (Nair & Pillai, 2023). Continuous GMP education and industry-academia collaboration are essential to building long-term compliance capacity.

Regulatory Infrastructure and Inspection Capacity

India's fragmented inspection capacity has historically constrained enforcement. To address this, CDSCO is enhancing inspector training and adopting **risk-based inspection tools**. Yet, state-level variability persists, posing risks of uneven implementation (MoHFW, 2024).

Data Management and Technological Gaps

Digital transformation brings cybersecurity and data authenticity challenges. Smaller firms may lack resources for robust IT validation and secure electronic systems, creating potential vulnerabilities (Kumar & Patel, 2024).

Implementation Roadmap and Monitoring

While the government aims for complete compliance by 2027, consistent follow-up, industry mentorship, and auditing mechanisms are required to ensure long-term sustainability. These elements form the cornerstone of policy effectiveness in the post-amendment era.

CONCLUSION:

The amendments to **Schedule M** mark a transformative step in the evolution of India's pharmaceutical regulatory landscape, reinforcing the nation's commitment to global quality, safety, and efficacy standards. By aligning domestic **Good Manufacturing Practices (GMP)** with international frameworks such as **WHO-GMP** and **PIC/S**, the revised Schedule M establishes a more robust and risk-based quality management system across the pharmaceutical sector.

The study reveals that these amendments significantly influence multiple facets of pharmaceutical manufacturing — from facility design and equipment qualification to documentation, process validation, and data integrity. The strengthened emphasis on **Quality Risk Management (QRM)**, **Computerized System Validation (CSV)**, and **Pharmaceutical Quality Systems (PQS)** encourages manufacturers to adopt a culture of continuous improvement and scientific decision-making.

While the regulatory upgrade offers long-term benefits in enhancing product reliability and fostering international acceptance, it also introduces short-term challenges. Small and medium enterprises (SMEs) may face financial and infrastructural constraints in achieving full compliance within the stipulated timelines. However, with appropriate regulatory guidance, phased implementation, and industry-government collaboration, these hurdles can be effectively mitigated.

In conclusion, the amended Schedule M is expected to elevate the quality benchmark of Indian pharmaceutical manufacturing, reduce instances of non-compliance, and strengthen India's position as a trusted global supplier of safe and efficacious medicines. The reform not only modernizes the regulatory framework but also sets a foundation for innovation-driven, quality-centric pharmaceutical growth in the coming decades.

REFERENCES:

1. Central Drugs Standard Control Organisation (CDSCO). (2024). *Revised Schedule M Guidelines for Good Manufacturing Practices*. Ministry of Health and Family Welfare, Government of India.
2. Chaudhuri, S. (2005). *The Indian Pharmaceutical Industry: Growth and Prospects*. Oxford University Press.
3. Department of Pharmaceuticals. (2023). *Annual Report 2022–23*. Government of India.
4. Gupta, R., Patel, M., & Rao, S. (2019). Quality compliance trends in Indian pharmaceutical manufacturing. *Journal of Regulatory Science, 7*(3), 22–31.
5. Jain, A., & Mehta, K. (2022). Data integrity challenges in Indian drug manufacturing. *International Journal of Pharmaceutical Quality Assurance, 13*(4), 245–253.
6. Kumar, V., Singh, D., & Rani, P. (2023). Advancing GMP compliance through risk-based approaches in India. *Asian Journal of Pharmacy Practice, 16*(2), 88–96.
7. Lalitha, N. (2018). *Intellectual Property and Innovation: Indian Pharmaceutical Industry*. Springer.
8. MoHFW. (2024). *Gazette Notification on Revised Schedule M (Good Manufacturing*

Practices), 2024. Ministry of Health and Family Welfare, New Delhi.

9. Pharmaceuticals Export Promotion Council of India (Pharmexcil). (2024). *Export Statistics 2023–24*.
10. Press Information Bureau (PIB). (2024). *India's Pharmaceutical Sector Overview.* Government of India.